

Cost Analysis of Glaucoma Medications

American Journal of Ophthalmology

145, 106-113

DOI: [10.1016/j.ajo.2007.08.041](https://doi.org/10.1016/j.ajo.2007.08.041)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy. British Journal of Ophthalmology, 2002, 86, 691-695.	3.9	25
4	The Economic Implications of Glaucoma. Pharmacoeconomics, 2007, 25, 287-308.	3.3	59
5	Best-Spectacle Corrected Visual Acuity before Excimer Laser Refractive Surgery. American Journal of Ophthalmology, 2008, 145, 1109-1110.	3.3	0
6	Cost Analysis of Glaucoma Medications. American Journal of Ophthalmology, 2008, 145, 1108-1109.	3.3	6
7	Health Care Charges for Patients with Ocular Hypertension or Primary Open-angle Glaucoma. Ophthalmology, 2008, 115, 633-638.e4.	5.2	14
8	Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US. Current Medical Research and Opinion, 2008, 24, 2905-2918.	1.9	56
9	Medical Management of Glaucoma. International Ophthalmology Clinics, 2008, 48, 115-141.	0.7	11
10	Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database. Clinical Ophthalmology, 2008, 2, 321.	1.8	7
11	Considerations in glaucoma therapy: fixed combinations versus their component medications. Clinical Ophthalmology, 0, , 1.	1.8	49
12	Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden. Clinical Ophthalmology, 2009, 3, 471.	1.8	1
14	iStent [®] : trabecular micro-bypass stent for open-angle glaucoma. Expert Review of Ophthalmology, 2010, 5, 443-450.	0.6	1
15	Anti-glaucoma drug-loaded contact lenses prepared using supercritical solvent impregnation. Journal of Supercritical Fluids, 2010, 53, 165-173.	3.2	86
16	Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension. Clinical Ophthalmology, 2010, 4, 1331.	1.8	8
17	Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opinion on Pharmacotherapy, 2010, 11, 959-968.	1.8	18
18	Automatic glaucoma diagnosis from fundus image. , 2011, 2011, 3383-6.		18
19	Resources use, costs and effectiveness of non-penetrating deep sclerectomy according to glaucoma stage. Arquivos Brasileiros De Oftalmologia, 2011, 74, 400-404.	0.5	6
20	Cost-Effectiveness Analysis of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology, 2012, 119, 1679-1684.	5.2	33
21	Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues. Drugs, 2012, 72, 1355-1371.	10.9	25

#	ARTICLE	IF	CITATIONS
22	Cost-effectiveness comparison between non-penetrating deep sclerectomy and maximum-tolerated medical therapy for glaucoma within the Brazilian National Health System (SUS). <i>Arquivos Brasileiros De Oftalmologia</i> , 2012, 75, 11-15.	0.5	8
23	Comparing the efficacy of the monocular trial treatment paradigm with multiple measurements of intraocular pressure before and after treatment initiation in primary open-angle glaucoma. <i>Clinical Ophthalmology</i> , 2012, 6, 491.	1.8	1
24	The Cost of Glaucoma Care Provided to Medicare Beneficiaries from 2002 to 2009. <i>Ophthalmology</i> , 2013, 120, 2249-2257.	5.2	38
25	MMPs in the Trabecular Meshwork: Promising Targets for Future Glaucoma Therapies?. , 2013, 54, 7756.		87
26	Cost-Effectiveness of Treating Normal Tension Glaucoma. , 2013, 54, 3394.		14
27	Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting. <i>Family Practice</i> , 2014, 31, 453-461.	1.9	39
28	A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 1136.	1.1	3
29	Glaucoma Screening Using Relative Afferent Pupillary Defect. <i>Journal of Glaucoma</i> , 2014, 23, 169-173.	1.6	16
30	Economic Analysis of the Ex-PRESS Miniature Glaucoma Device Versus Trabeculectomy. <i>Journal of Glaucoma</i> , 2014, 23, 385-390.	1.6	31
31	Topical glaucoma therapy cost in Mexico. <i>International Ophthalmology</i> , 2014, 34, 241-249.	1.4	5
32	Comparison of United States and Canadian Glaucoma Medication Costs and Price Change from 2006 to 2013. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-8.	1.3	16
33	Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial. <i>Ophthalmic Epidemiology</i> , 2015, 22, 380-386.	1.7	17
34	Economics of Glaucoma Care. , 2015, , 20-29.		0
35	Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 808-817.	0.9	16
36	Characterization of Glaucoma Medication Adherence in Kaiser Permanente Southern California. <i>Journal of Glaucoma</i> , 2016, 25, 22-26.	1.6	17
37	A HW/SW embedded system for accelerating diagnosis of glaucoma from eye fundus images. , 2016, , .		1
38	Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana—a retrospective cross-sectional study from three referral facilities. <i>BMC Health Services Research</i> , 2016, 16, 282.	2.2	21
39	Pediatric Glaucoma: Pharmacotherapeutic Options. <i>Paediatric Drugs</i> , 2016, 18, 209-219.	3.1	13

#	ARTICLE	IF	CITATIONS
40	COST-COMPARISON OF TWO TRABECULAR MICRO-BYPASS STENTS VERSUS SELECTIVE LASER TRABECULOPLASTY OR MEDICATIONS ONLY FOR INTRAOCULAR PRESSURE CONTROL FOR PATIENTS WITH OPEN-ANGLE GLAUCOMA. Value in Health, 2016, 19, A301.	0.3	0
41	Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma. American Journal of Ophthalmology, 2016, 163, 70-74.e1.	3.3	17
42	Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medications only for intraocular pressure control for patients with open-angle glaucoma. Journal of Medical Economics, 2017, 20, 760-766.	2.1	32
43	Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway. Expert Opinion on Therapeutic Targets, 2017, 21, 1037-1050.	3.4	41
44	Cost comparison of commonly used postoperative topical ophthalmic antibiotics. Journal of Cataract and Refractive Surgery, 2017, 43, 1322-1327.	1.5	9
45	Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Human Molecular Genetics, 2017, 26, 1230-1246.	2.9	60
46	Variation in the volume of lubricating eyedrops available in the brazilian market. Revista Brasileira De Oftalmologia, 2017, 76, .	0.1	1
47	OCULAR DRUG DELIVERY SYSTEM USING OPEN-SOURCE SYRINGE PUMP. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 152.	0.3	6
48	Cost-utility Analysis of Primary Open-angle Glaucoma according to Follow-up Observation Period. Journal of Korean Ophthalmological Society, 2018, 59, 842.	0.2	0
49	A Novel Method to Eliminate Preservatives in Eye Drops. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 584-589.	1.4	2
50	The Effect of an Educational Intervention on Adherence to Intraocular Pressure-Lowering Medications in a Large Cohort of Older Adults with Glaucoma. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1284-1294.	0.9	14
51	Comparison of United States and International Ophthalmic Drug Pricing. Ophthalmology, 2019, 126, 1358-1365.	5.2	11
52	Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostaglandins for Open-Angle Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 145-160.	1.4	10
53	<p>North American cost analysis of brand name versus generic drugs for the treatment of glaucoma</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 789-798.	1.9	6
54	Medication Burden for Patients With Bacterial Keratitis. Cornea, 2019, 38, 933-937.	1.7	17
55	The Current Status of Glaucoma and Glaucoma Care in Sub-Saharan Africa. Asia-Pacific Journal of Ophthalmology, 2019, 7, 375-386.	2.5	19
56	Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma. Progress in Retinal and Eye Research, 2020, 76, 100801.	15.5	28
57	Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology, 2020, 2020, 1-5.	1.3	5

#	ARTICLE	IF	CITATIONS
58	<p>Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study</p>. Clinical Ophthalmology, 2020, Volume 14, 729-739.	1.8	12
59	Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events. American Journal of Clinical Dermatology, 2021, 22, 89-99.	6.7	6
60	Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel. Advanced Science, 2021, 8, 2001908.	11.2	20
61	Medical Costs of and Changes in Glaucoma Treatment among Patients Newly Starting Glaucoma Care. Current Eye Research, 2021, 46, 1-8.	1.5	2
62	Assessing financial insecurity among common eye conditions: a 2016-2017 national health survey study. Eye, 2022, 36, 2044-2051.	2.1	5
63	Medical Management of Glaucoma. , 2013, , .		3
64	Medical Management of Glaucoma. , 2013, , 71-100.		2
65	Cost-effectiveness of glaucoma management with monotherapy medications in Egypt. Journal of Advanced Pharmaceutical Technology and Research, 2017, 8, 25.	1.0	5
66	Adherence and Persistence with Glaucoma Therapy: Brimonidine/Timolol versus Dorzolamide/Timolol and Various Two-Bottle Combinations. Journal of Clinical & Experimental Ophthalmology, 2012, 03, .	0.1	10
68	Custo-efetividade dos anÃlogos de prostaglandinas no Brasil. Revista Brasileira De Oftalmologia, 2008, 67, 281-286.	0.1	1
70	Medical Treatment: First Line Agents and Monotherapy. , 2010, , 195-201.		0
71	Volumetric and cost evaluation study of glaucoma medical therapy. International Journal of Applied & Basic Medical Research, 2015, 5, 96.	0.5	2
72	A comparison of clinical trial and model-based cost estimates in glaucoma - The case of repeat laser trabeculoplasty In Ontario. Journal of Hospital Administration, 2017, 6, 46.	0.1	0
73	A Pharmacoeconomic Analysis to Determine the Relative Cost-effectiveness of Timolol 0.5%, Brinzolamide 1% and Brimonidine 0.2% Eye Drops in Treatment of Primary Open Angle Glaucoma/Ocular Hypertension. International Journal of Medical and Dental Sciences, 2019, 8, 1766-1774.	0.1	0
74	Considerations in glaucoma therapy: fixed combinations versus their component medications. Clinical Ophthalmology, 2010, 4, 1-9.	1.8	74
75	Incremental Health Care Expenditures Associated With Glaucoma in the United States: A Propensity Score-matched Analysis. Journal of Glaucoma, 2022, 31, 1-7.	1.6	5
76	Improvement of PnPP-19 peptide bioavailability for glaucoma therapy: Design and application of nanowafers based on PVA. Journal of Drug Delivery Science and Technology, 2022, 74, 103501.	3.0	2
77	In-Vitro Study on Permeation of different Semi-solid dosage forms of Timolol Maleate using Franz cell. Research Journal of Pharmacy and Technology, 2022, , 2721-2726.	0.8	1

#	ARTICLE	IF	CITATIONS
78	Application of Machine Learning Predictive Models for Early Detection of Glaucoma Using Real World Data. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 2445.	2.5	4
79	Segmental Suture Gonioscopy-Assisted Transluminal Trabeculotomy: Comparison of Superior Versus Inferior Hemisphere Outcomes. <i>Journal of Glaucoma</i> , 2023, 32, 396-406.	1.6	2
80	Changes of the Types and Daily Costs of Topical Antiglaucoma Medications from 2006 to 2021 in China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2023, 2023, 1-9.	1.5	0
81	Matrix metalloproteinase-3 (MMP-3) mediated gene therapy for glaucoma. <i>Science Advances</i> , 2023, 9, .	10.3	5
82	Efficacy of gonioscopy-assisted transluminal trabeculotomy in advanced-age glaucoma patients. <i>Canadian Journal of Ophthalmology</i> , 2023, , .	0.7	0
83	Factors Affecting Glaucoma Medication Adherence and Interventions to Improve Adherence: A Narrative Review. <i>Ophthalmology and Therapy</i> , 2023, 12, 2863-2880.	2.3	2
84	Cost-utility analysis of treating mild stage normal tension glaucoma by surgery in China: a decision-analytic Markov model. <i>Cost Effectiveness and Resource Allocation</i> , 2024, 22, .	1.5	0